EMA confirms recommendation for non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna

View source ↗

Summary

EMA confirms recommendation to non-renew the marketing authorisation for Translarna, a medicine for Duchenne muscular dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Translarna (ataluren)